The clinical significance of MGMT promoter methylation in the treatment and progno-sis of glioma patients
10.3969/j.issn.1000-8179.2019.12.327
- VernacularTitle:MGMT启动子甲基化对神经胶质瘤患者治疗及预后的临床意义
- Author:
Xuetao HAN
1
;
Huandi ZHOU
;
Xiaoying XUE
Author Information
1. 河北医科大学第二医院放疗科(石家庄市050000)
- Keywords:
gliomas;
MGMT promoter methylation;
prognosis;
therapeutic regimen
- From:
Chinese Journal of Clinical Oncology
2019;46(12):645-648
- CountryChina
- Language:Chinese
-
Abstract:
Adjuvant temozolomide-based chemotherapy has become the standard of care for most postoperative glioma patients. However, a large proportion of these patients do not respond to temozolomide. DNA repair enzyme O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation has emerged as an important molecular marker in patients with gliomas. It is associated with prognosis and resistance to alkylated drugs such as temozolomide. MGMT promoter methylation is the key mechanism of MGMT gene silencing, thereby inhibiting DNA repair and increasing the sensitivity of chemotherapy. We reviewed current data on the prog-nostic and predictive relevance of MGMT testing and clinical trials, summarized the clinical application of MGMT promoter methyla-tion, in order to provide reference for the individualized treatment of glioma patients.
